This company has shut down. ITeos Therapeutics is no longer operating — its last tracked round was a Post-IPO Equity in 2024.
Explore the Startup GraveyardITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
ITeos Therapeutics has raised $120.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2024.
ITeos Therapeutics's investors include RA Capital Management, Janus Henderson Investors, RTW Investments, Invus, MPM Capital.
ITeos Therapeutics is headquartered in Cambridge, United States.
ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.
ITeos Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ITeos Therapeutics — Funding & Investors." VCBacked, May 10, 2024, https://www.vcbacked.co/company/iteos-therapeutics. Accessed November 12, 2026.
VCBacked. (2024). ITeos Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/iteos-therapeutics
{{cite web |title=ITeos Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/iteos-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at ITeos Therapeutics? Request a listing update